EpiSign

Greenwood Diagnostic Laboratories in partnership with London Health Science Centre present EpiSign!

GGC Launches EpiSign, a Novel Clinical Test for Epigenetic Changes
GGC Launches EpiSign, a Novel Clinical Test for Epigenetic Changes

EpiSign is an assay designed to readily identify proven and reproducible epigenetic signatures by assessing genome-wide methylation.

EpiSign has multiple applications in the clinical setting by providing an additional diagnostic tool beyond the current sequencing and copy number technology paradigm.  EpiSign can detect multiple methylation abnormalities associated with certain imprinting or triplet repeat conditions. This test can also identify disease-specific methylation patterns involving multiple loci across the genome. 

Assessment of these distinct methylation patterns can be a useful screening tool for these disorders in the diagnostic work-up or can be applied in a more targeted fashion to help resolve variants of uncertain clinical significance.

Version 3 launched in June 2021 increasing the number to more than 50 identifiable disorders.


One Assay. Two Options.

Episign is offered as two different tests to suit the needs of your patient.

  • EpiSign Complete v.3
    A comprehensive analysis including 50 disorders.
  • EpiSign Variant   
    A targeted review of the methylation data intended to resolve variants of uncertain clinical signficance. 

One Mother's Story

After a long three-year struggle trying to have children, our son, Charlie, was born on April 18, 2009. He was our miracle...perfect in every way! When Charlie was five days old, our pediatrician called to notify us that one of the numbers from the heel prick test was a bit high. We headed to the hospital that afternoon for more tests. I will never forget the following day. It was cool and crisp - not a cloud in the sky. The next thing I know, our ...

In The News